Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity

BORIS DOI
Publisher DOI
PubMed ID
36087505
Date of Publication
2022
Publication Type
Article
Subject(s)
Language(s)
en
Contributor(s)
Nowak, Albina
Dormond, Olivier
Monzambani, Véronique
Barbey, Frédéric
Additional Credits
Series
Molecular genetics and metabolism
Publisher
Elsevier
ISSN
1096-7192
Access(Rights)
open.access
Show full item